Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3335413 | Transfusion and Apheresis Science | 2011 | 9 Pages |
Abstract
Large-volume leukapheresis (LVL) differs from standard leukapheresis by increased blood flow and an altered anticoagulation regimen. An open issue is to what degree a further increase in processed blood volume is reasonable in terms of higher yields and safety. In 30 LVL performed in patients with hematologic malignancies, 6 total blood volumes were processed. LVL resulted in a higher CD34+ cell yield without a change in graft quality. Although a marked platelet decrease can be expected, LVL is safe and can be recommended as the standard procedure for patients who mobilize low numbers of CD34+ cells and when high number of CD34+ cells are required.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Ines Bojanic, Klara Dubravcic, Drago Batinic, Branka Golubic Cepulic, Sanja Mazic, Darko Hren, Damir Nemet, Boris Labar,